BioSpace News Archive

On May 23, 2019, the US-based chemical company BOC Sciences announces to upgrade its ADCs product line for cancer research as a targeted drug therapy. In addition to providing top quality ADCs that are GMP manufactured, BOC Sciences also provides custom synthesis service to develop antibody-drug conjugates based on individual needs for all phases of drug development.

BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), today announced positive top line data from its Phase 1 pharmacokinetic (PK) (bioavailability) and safety study of BXCL501, a proprietary sublingual thin-film formulation of dexmedetomidine (Dex), for the acute treatment of agitation across multiple neuropsychiatric indications.

Bausch Health Companies Inc. announced the results to date of its pending cash tender offers to purchase up to $1,500,000,000 aggregate principal amount of its outstanding notes listed in the table below, as well as the anticipated early settlement date for the Tender Offers on May 24, 2019.

THINK Surgical, Inc. announces completion of enrollment for the U.S. investigational clinical study and submission of the 510 to obtain clearance from FDA to market its active robot, TSolution One®, for use in total knee replacement procedures.

Oncoceutics, Inc. announced that the latest efficacy data for the use of ONC201 in adult recurrent H3 K27M-mutant glioma will be presented in an Oral Abstract Session at the 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

IDEAYA Biosciences, Inc. (Nasdaq:IDYA) has announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $10.00 per share, before underwriting discounts and commissions, as detailed in the company press release

Polarean Imaging plc (AIM: POLX), announces that upon the recommendation of the Company’s Remuneration Committee it has granted options over a total of 1,200,000 ordinary shares of 0.00037p each in the Company (“Ordinary Shares”) to Chuck Osborne, Chief Financial Officer

Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announced that it has submitted a response to the European Medicines Agency’s (EMA) second Day 180 list of outstanding issues for ATIR101

Centauri Therapeutics (“Centauri”) is an immunotherapy company active in oncology and infectious diseases.

AdAlta Limited (ASX: 1AD) is pleased to announce the placement of up to 33,333,333 fully paid ordinary shares in the Company to sophisticated and institutional investors at a price of $0.15 per share to raise $5 million (before costs) (Placement).